[[1] Bäck M. Leukotriene signaling in atherosclerosis and
ischemia. Cardiovasc Drugs Ther. 2009;23:41–48.
10.1007/s10557-008-6140-9]Search in Google Scholar
[[2] Bennett AM, Williams GM. Reduction of rat liver endoplasmic
reticulum Ca2+-ATPase activity and mobilization
of hepatic intracellular calcium by ciprofibrate, a peroxisome
proliferator. Biochem. Pharmacol. 1992;43:595–605.
]Search in Google Scholar
[[3] Cinti DL, Moldeus P, Schenkman JB. Kinetic parameters of
drug-metabolizing enzymes in Ca2+-sedimented microsomes
from rat liver. Biochem Pharmacol. 1972;21:3249–56.
10.1016/0006-2952(72)90089-5]Search in Google Scholar
[[4] Bradford MM. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal.Biochem.
1976;72:248–254.
]Search in Google Scholar
[[5] Feltenmark S, Gautam N, Brunnström A, Griffiths W, Backman
L, Edenius Ch, Lindbom L, Björkholm M, Claesson
HE. Eoxins are proinflammatory arachidonic acid metabolites
produced via the 15-lipoxygenase-1 pathway in
human eosinophils and mast cells. Proc. Natl. Acad. Sci.
USA 2008;105:680–685.
10.1073/pnas.0710127105220659618184802]Search in Google Scholar
[[6] Grundy SM. Obesity, Metabolic Syndrome, and Cardiovascular
Disease. The Journal of Clinical Endocrinology &
Metabolism 2004;89:2595–2600.
10.1210/jc.2004-037215181029]Search in Google Scholar
[[7] Hogaboom GK, Cook M, Newton JF, Varrichio A, Shorr RG,
Sarau HM, Crooke ST. Purification, characterization, and
structural properties of a single protein from rat basophilic
leukemia (RBL-1) cells possessing 5-lipoxygenase
and leukotriene A4 synthetase activities. Mol. Pharmacol.
1986;30:509–510.
]Search in Google Scholar
[[8] Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL.
12/15-Lipoxygenase Products Induce Inflammation and
Impair Insulin Signaling in 3T3-L1 Adipocytes. Obesity
2009;17:1657–1663.
10.1038/oby.2009.192288774119521344]Search in Google Scholar
[[9] Jiao HL, Zhao BL. Cytotoxic Effect of Peroxisome Proliferator
Fenofibrate on Human HepG2 Hepatoma Cell Line
and Relevant Mechanisms. Toxicology and Applied Pharmacology
2002;185:172–179.
10.1006/taap.2002.953812498734]Search in Google Scholar
[[10] Kemal, C, Louis-Flamberg P, Krupinsky-Olsen R, Shorter
AL. Reductive inactivation of soybean lipoxygenase
1 by catechols: a possible mechanism for regulation
of lipoxygenase activity. Biochemistry 1987;26:7064–
7072.
10.1021/bi00396a0313122826]Search in Google Scholar
[[11] Laemmli UK. Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature
1970;227:680–685.
10.1038/227680a05432063]Search in Google Scholar
[[12] Nesterenko MV, Tilley M, Upton SJ. A simple modification
of Blum’s silver stain method allows for 30 minute detection
of proteins in polyacrylamide gels. J. Biochem. Biophys.
Methods 1994;28:239–242.
]Search in Google Scholar
[[13] Pace-Asciak CR. The hepoxilins and some analogues: a
review of their biology. Brit. J. Pharm. 2009;158:972–981.
]Search in Google Scholar
[[14] Radmark O, Werz O, Steinhilber D. 5-Lipoxygenase: regulation
of expression and enzyme activity. Trends Biochem.
Sci. 2007;32:332–341.
]Search in Google Scholar
[[15] Riccioni G, Zanasi A, Vitulano N, Mancini B, D’orazio N.
Leukotrienes in Atherosclerosis: New Target Insights
and Future Therapy Perspectives. Mediators of Inflamm.
2009;Article ID 737282, 6 pages.
10.1155/2009/737282281754320150962]Search in Google Scholar
[[16] Romano M. Lipid mediators: lipoxin and aspirin-triggered
15-epi-lipoxins. Inflamm. Allergy Drug Targets 2006;5:
81–90.
]Search in Google Scholar
[[17] Schindler CH. The metabolic syndrome as an endocrine
disease: is there an effective pharmacotherapeutic strategy
optimally targeting the pathogenesis? Therapeutic
Advances in Cardiovascular Disease 2007;1:7–26.10.1177/175394470708266219124392]Search in Google Scholar
